E-cigarette Cessation in Adults Who Co-use Cannabis (NCT06688539)
A Prospective Trial of Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
Who can join: Review the eligibility criteria below.
Location: MUSC Charleston — Charleston, South Carolina
Age range: 18 Years to 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- MUSC Charleston — Charleston, South Carolina
- MUSC Lancaster — Lancaster, South Carolina
- Behavioral Health Services of Pickens County — Pickens, South Carolina
📞 Contact the Study Coordinator
Phone: (864) 898-2992
Email: chapmanb@musc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Nicotine Dependence
- Targeting Orexin to Treat Nicotine Dependence — Belmont, Massachusetts
- Electronic Cigarettes and Reactivity to Smoking Cues — Belmont, Massachusetts
- Sex Differences in E-Cigarette Perception — New Haven, Connecticut
- NeuroControl of Nicotine Dependence — Columbia, Missouri
- Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch Use — Los Angeles, California
- Orexin s Role in the Neurobiology of Substance Use Disorder — Baltimore, Maryland
Explore by condition: All Nicotine Dependence clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.